Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 16:10:923485.
doi: 10.3389/fpubh.2022.923485. eCollection 2022.

Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis

Zhe Chen  1 , Yingying Peng  2   3 , Xiaolei Wu  1 , Bo Pang  1 , Fengwen Yang  1 , Wenke Zheng  1 , Chunxiang Liu  1 , Junhua Zhang  1
Affiliations
Meta-Analysis

Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis

Zhe Chen et al. Front Public Health. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) causes life-threatening with the high-fatality rates and spreads with high-infectious disease worldwide. We aimed to systematically review the comorbidities and complications of COVID-19 that are associated with various disease severity, progression, and mortality in China, to provide contemporary and reliable estimates in settings with centralized isolation and hospitalization.

Methods: In this systematic review and meta-analysis, we searched four main English language databases, and four main Chinese language databases for observational studies published from inception to January 2022, to identify all the related comorbidities and complications of COVID-19, in the China region with centralized isolation and hospitalization, with disease severity, progression, and mortality. Literature search, data extraction, and quality assessment were independently conducted by two reviewers. We used the generalized linear mixed model to estimate pooled effect sizes for any comorbidities and complications, and subgroup in gender ratio was done to further address the potential heterogeneity.

Results: Overall, 187 studies describing 77,013 patients, namely, 54 different comorbidities and 46 various complications of COVID-19, were identified who met our inclusion criteria. The most prevalent comorbidities were hypertension [20.37% 95% CI (15.28-26.63), 19.29% (16.17-22.85), 34.72% (31.48-38.10), and 43.94% (38.94-49.06)] and diabetes [7.84% (5.78-10.54), 8.59% (7.25-10.16), 17.99% (16.29-19.84), and 22.68% (19.93-25.69)] in mild, moderate, severe, and critical cases. The most prevalent complications were liver injury [10.00% (1.39-46.72), 23.04% (14.20-35.13), and 43.48% (39.88-47.15)] in mild, moderate, and severe cases, and acute respiratory distress syndrome [ARDS; 94.17% (20.78-99.90)] and respiratory failure [90.69% (28.08-99.59)] in critical cases. Renal insufficiency [odds ratio (OR) 17.43 (6.69-45.43)] in comorbidities and respiratory failure [OR 105.12 (49.48-223.33)] in complications were strongly associated in severe/critical than in mild/moderate cases. The highest estimated risk in intensive care unit (ICU) admission, progression, and mortality was an autoimmune disease, nervous system disease, and stroke in comorbidities, shock, and ARDS in complications.

Conclusion: Comorbidities and complications in inpatients with COVID-19 were positively associated with increased risk in severe and critical cases, ICU admission, exacerbation, and death during centralized isolation and hospitalization. Prompt identification of comorbidities and complications in inpatients with COVID-19 can enhance the prevention of disease progression and death and improve the precision of risk predictions.

Keywords: COVID-19; centralized isolation and hospitalization; comorbidities; complications; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of evidence search and selection. CNKI, China National Knowledge Infrastructure; Wan Fang Data, Wanfang Data Knowledge Service Platform; VIP, VIP information resource integration service platform databases; SinoMed, Chinese biomedical literature service system.
See this image and copyright information in PMC

References

    1. Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. . COVID-19 and resilience of healthcare systems in ten countries. Nat Med. (2022) 28:1314-24. 10.1038/s41591-022-01750-1 - DOI - PMC - PubMed
    1. Haldane V, De Foo C, Abdalla SM, Jung AS, Tan M, Wu S, et al. . Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med. (2021) 27:964–80. 10.1038/s41591-021-01381-y - DOI - PubMed
    1. COVID-19 Excess Mortality Collaborators . Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. (2022) 399:P1513–6. 10.1016/S0140-6736(21)02796-3 - DOI - PMC - PubMed
    1. Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. . Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis. (2021) 21:203–12. 10.1016/S1473-3099(20)30769-6 - DOI - PMC - PubMed
    1. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. . Infectious disease in an era of global change. Nat Rev Microbiol. (2022) 20:193–205. 10.1038/s41579-021-00639-z - DOI - PMC - PubMed

Publication types